147 related articles for article (PubMed ID: 34703008)
41. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
42. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
43. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
44. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.
Phipps AI; Alwers E; Harrison T; Banbury B; Brenner H; Campbell PT; Chang-Claude J; Buchanan D; Chan AT; Farris AB; Figueiredo JC; Gallinger S; Giles GG; Jenkins M; Milne RL; Newcomb PA; Slattery ML; Song M; Ogino S; Zaidi SH; Hoffmeister M; Peters U
Gastroenterology; 2020 Jun; 158(8):2158-2168.e4. PubMed ID: 32088204
[TBL] [Abstract][Full Text] [Related]
45. Double
Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
[TBL] [Abstract][Full Text] [Related]
46. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
47.
Summers MG; Smith CG; Maughan TS; Kaplan R; Escott-Price V; Cheadle JP
Clin Cancer Res; 2017 Jun; 23(11):2742-2749. PubMed ID: 27815357
[No Abstract] [Full Text] [Related]
48. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
49. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
50. Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients.
Gorukmez O; Yakut T; Gorukmez O; Sag SO; Karkucak M; Kanat O
Asian Pac J Cancer Prev; 2016; 17(3):1175-9. PubMed ID: 27039744
[TBL] [Abstract][Full Text] [Related]
51. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer.
Losi L; Bouzourene H; Benhattar J
Oncol Rep; 2007 May; 17(5):1095-9. PubMed ID: 17390050
[TBL] [Abstract][Full Text] [Related]
52. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
53. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
54. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
Bagadi SB; Sanghvi M; Nair SB; Das BR
Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190
[TBL] [Abstract][Full Text] [Related]
55. Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.
Mehta RS; Song M; Nishihara R; Drew DA; Wu K; Qian ZR; Fung TT; Hamada T; Masugi Y; da Silva A; Shi Y; Li W; Gu M; Willett WC; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
Gastroenterology; 2017 Jun; 152(8):1944-1953.e1. PubMed ID: 28249812
[TBL] [Abstract][Full Text] [Related]
56. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
57. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
58. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
59. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
